Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
1.08B
-
Number of holders
-
127
-
Total 13F shares, excl. options
-
34.4M
-
Shares change
-
+2.35M
-
Total reported value, excl. options
-
$209M
-
Value change
-
+$13.2M
-
Put/Call ratio
-
3.75
-
Number of buys
-
70
-
Number of sells
-
-50
-
Price
-
$6.08
Significant Holders of ImmunityBio, Inc. - Common Stock, par value $0.0001 per share (IBRX) as of Q4 2021
154 filings reported holding IBRX - ImmunityBio, Inc. - Common Stock, par value $0.0001 per share as of Q4 2021.
ImmunityBio, Inc. - Common Stock, par value $0.0001 per share (IBRX) has 127 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 34.4M shares
of 1.08B outstanding shares and own 3.19% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (7.14M shares), STATE STREET CORP (6.22M shares), BlackRock Inc. (5.34M shares), GEODE CAPITAL MANAGEMENT, LLC (1.56M shares), JPMORGAN CHASE & CO (1.27M shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (949K shares), Rafferty Asset Management, LLC (825K shares), ALLEN HOLDING INC /NY (688K shares), NORTHERN TRUST CORP (685K shares), and CHARLES SCHWAB INVESTMENT MANAGEMENT INC (476K shares).
This table shows the top 127 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.